Advertisement
Advertisement

DNLI

DNLI logo

Denali Therapeutics Inc. Common Stock

18.62
USD
Sponsored
-0.77
-3.97%
May 15, 15:59 UTC -4
Closed
exchange

After-Market

18.63

+0.01
+0.05%

Denali Therapeutics Inc. Common Stock Profile

About

Denali Therapeutics, a biopharmaceutical company, is developing a wide and innovative portfolio of targeted therapeutic candidates, which are engineered to cross the blood-brain barrier for neurodegenerative diseases. It has 5 clinical-stage programs, a leucine-rich repeat kinase 2 inhibitor program partnered with Biogen to address Parkinson's disease, an eukaryotic translation initiation factor 2B activator program to address diseases such as amyotrophic lateral sclerosis and frontotemporal dementia (FTD), the ETV:IDS program, which utilizes the company's enzyme transport vehicle technology, and is designed to restore iduronate 2-sulfatase and reduce glycosaminoglycans, in patients with mucopolysaccharidosis II, and two separate receptor interacting serine/threonine protein kinase 1 inhibitor programs, both partnered with Sanofi. It also has a collaboration and option agreement with Takeda Pharmaceutical Co. Ltd. Takeda has exercised its option to jointly develop and commercialize DNL593 with the company.

Info & Links

CEO

Ryan J. Watts

Headquarters

161 OYSTER POINT BLVD.
SOUTH SAN FRANCISCO, CA 94080, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.denalitherapeutics.com

Auditor

Ernst & Young LLP

Share holders

143

Employees

503

Denali Therapeutics Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

2.96B

Enterprise Value

2.76B

Enterprise Value/EBITDA(ttm)

-4.97

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

2.79

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-50.13%

Return on Invested Capital(ttm)

-50.04%

Return on Assets(ttm)

-44.20%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-554.41M

Net Income Available to Common(ttm)

-512.54M

Diluted EPS(ttm)

-2.97

Share Statistics

Beta (5Y Monthly)

1.10

52-Week Change

31.50%

S&P 500 52-Week Change

24.23%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

158.59M

Dividend Yield

0.00%

Float4

138.77M

% Held by Insiders

12.50%

% Held by Institutions

92.92%

Balance Sheet

Total Cash(mrq)

867.88M

Total Cash Per Share(mrq)

5.47

Total Debt(mrq)

5.53M

Total Debt/Equity(mrq)

0.55%

Current Ratio(mrq)

9.16%

Quick Ratio(mrq)

9.16%

Book Value Per Share(mrq)

6.49

Cash Flow

Operating Cash Flow Per Share(ytd)

-2.39

Free Cash Flow(ytd)

-422.10M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement